Company & Sponsor Intelligence
National and Kapodistrian University of Athens
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting2
Completed1
Countries1
Therapeutic footprint
anxietymultiple_sclerosisout_of_scope
Indexed studies
NCT07329127The Prevalence of Osmophobia in Migraine and Tension-Type Headache Patients and Its Association With Migraine Symptoms Over a Period of 6 Months
anxiety · GreeceCOMPLETED
anxiety · GreeceCOMPLETED
NCT06903130Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)
multiple_sclerosis · GreeceNOT_YET_RECRUITING
multiple_sclerosis · GreeceNOT_YET_RECRUITING
NCT06069310Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
out_of_scope · GreeceACTIVE_NOT_RECRUITING
out_of_scope · GreeceACTIVE_NOT_RECRUITING
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →